Logo image of MEIP

MEI PHARMA INC (MEIP) Stock Fundamental Analysis

NASDAQ:MEIP - Nasdaq - US55279B3015 - Common Stock - Currency: USD

2.25  +0.02 (+0.9%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to MEIP. MEIP was compared to 557 industry peers in the Biotechnology industry. MEIP has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, MEIP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MEIP was profitable.
MEIP had a negative operating cash flow in the past year.
MEIP had negative earnings in 4 of the past 5 years.
In the past 5 years MEIP reported 4 times negative operating cash flow.
MEIP Yearly Net Income VS EBIT VS OCF VS FCFMEIP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

MEIP's Return On Assets of -152.38% is on the low side compared to the rest of the industry. MEIP is outperformed by 85.64% of its industry peers.
The Return On Equity of MEIP (-162.03%) is worse than 64.45% of its industry peers.
Industry RankSector Rank
ROA -152.38%
ROE -162.03%
ROIC N/A
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
MEIP Yearly ROA, ROE, ROICMEIP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MEIP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MEIP Yearly Profit, Operating, Gross MarginsMEIP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

7

2. Health

2.1 Basic Checks

MEIP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MEIP has less shares outstanding
The number of shares outstanding for MEIP has been increased compared to 5 years ago.
There is no outstanding debt for MEIP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MEIP Yearly Shares OutstandingMEIP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
MEIP Yearly Total Debt VS Total AssetsMEIP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

MEIP has an Altman-Z score of -22.32. This is a bad value and indicates that MEIP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -22.32, MEIP is doing worse than 86.71% of the companies in the same industry.
There is no outstanding debt for MEIP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -22.32
ROIC/WACCN/A
WACC9.1%
MEIP Yearly LT Debt VS Equity VS FCFMEIP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 16.78 indicates that MEIP has no problem at all paying its short term obligations.
MEIP's Current ratio of 16.78 is amongst the best of the industry. MEIP outperforms 89.77% of its industry peers.
A Quick Ratio of 16.78 indicates that MEIP has no problem at all paying its short term obligations.
The Quick ratio of MEIP (16.78) is better than 89.77% of its industry peers.
Industry RankSector Rank
Current Ratio 16.78
Quick Ratio 16.78
MEIP Yearly Current Assets VS Current LiabilitesMEIP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

MEIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 157.67%, which is quite impressive.
Looking at the last year, MEIP shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
The Revenue has been growing by 67.72% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.81%
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%N/A

3.2 Future

MEIP is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -67.16% yearly.
Based on estimates for the next years, MEIP will show a very strong growth in Revenue. The Revenue will grow by 85.04% on average per year.
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5Y-67.16%
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5Y85.04%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MEIP Yearly Revenue VS EstimatesMEIP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 1B 2B 3B
MEIP Yearly EPS VS EstimatesMEIP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15 -20 -25

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 0.84, which indicates a rather cheap valuation of MEIP.
MEIP's Price/Earnings ratio is rather cheap when compared to the industry. MEIP is cheaper than 99.82% of the companies in the same industry.
When comparing the Price/Earnings ratio of MEIP to the average of the S&P500 Index (26.32), we can say MEIP is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for MEIP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 0.84
Fwd PE N/A
MEIP Price Earnings VS Forward Price EarningsMEIP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MEIP Per share dataMEIP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A cheap valuation may be justified as MEIP's earnings are expected to decrease with -37.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%

More info and screens

0

5. Dividend

5.1 Amount

MEIP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEI PHARMA INC

NASDAQ:MEIP (6/17/2025, 8:00:01 PM)

2.25

+0.02 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13
Earnings (Next)09-17 2025-09-17/amc
Inst Owners40.16%
Inst Owner Change-3.56%
Ins Owners1.3%
Ins Owner Change0%
Market Cap14.98M
Analysts43.33
Price Target6.12 (172%)
Short Float %0.04%
Short Ratio0.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend1.75
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.84
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.77
P/tB 0.77
EV/EBITDA N/A
EPS(TTM)2.67
EY118.67%
EPS(NY)-3.78
Fwd EYN/A
FCF(TTM)-5.46
FCFYN/A
OCF(TTM)-5.46
OCFYN/A
SpS0
BVpS2.93
TBVpS2.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -152.38%
ROE -162.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.78
Quick Ratio 16.78
Altman-Z -22.32
F-Score2
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)52.51%
Cap/Depr(5y)242.29%
Cap/Sales(3y)0.42%
Cap/Sales(5y)1.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.81%
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5Y-67.16%
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5Y85.04%
EBIT growth 1Y-200.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.82%
OCF growth 3YN/A
OCF growth 5YN/A